Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells

Abstract

Hypoxia initiates an adaptive physiological response in all organisms and plays a role in the pathogenesis of several human diseases. The hypoxia/HIF-inducible factor-1 (HIF-1) transcription factor mediates transcriptional responses to hypoxia by binding to a cis-acting hypoxia-responsive element (HRE) present within target genes. The use of the HIF-1/HRE system of gene regulation can be utilized as a mechanism to target expression of therapeutic genes to hypoxic cells or cells that have a constitutively active HIF-1/HRE pathway due to cell transformation. Given the rapid resistance of tumors to single therapeutic strategies, new vector systems need to be developed that can deliver multimodal therapy. Here we show that HREs function as classical enhancer elements and function bidirectionally to co-regulate the expression of two genes. We designed a large series of novel bidirectional hypoxia/HIF-responsive expression vectors using HREs derived from the human vascular endothelial growth factor (VEGF) and erythropoietin (EPO) genes. We measured the ability of these constructs to express the luciferase and LacZ/β-galactosidase (β-gal) reporter genes bidirectionally under normoxic (21% O2) versus hypoxic (1, 3, 5, and 10% O2) conditions by transient transfection in three human glioma cell lines (LN229, U251MG and U138MG). Nine constructs were identified that exhibited moderate to high inducibility at 1% O2 while maintaining tight regulation under normoxic conditions. Moreover, the level of activation was a function of O2 concentration and was exponential at O2 levels below 5%. These vectors will be valuable tools in a variety of gene therapy applications targeting pathological activation of the HIF-1/HRE pathway.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Semenza GL . HIF-1 and human disease: one highly involved factor Genes Dev 2000 14: 1983–1991

    CAS  PubMed  Google Scholar 

  2. Brown JM, Giaccia AJ . The unique physiology of solid tumors: opportunities (and problems) for cancer therapy Cancer Res 1998 58: 1408–1416

    CAS  PubMed  Google Scholar 

  3. Brown JM . Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies Mol Med Today 2000 6: 157–162

    Article  CAS  PubMed  Google Scholar 

  4. Semenza GL . Hypoxia, clonal selection, and the role of HIF-1 in tumor progression Crit Rev Biochem Mol Biol 2000 35: 71–103

    Article  CAS  PubMed  Google Scholar 

  5. Wenger RH, Gassmann M . Oxygen(es) and the hypoxia-inducible factor-1 Biol Chem 1997 378: 609–616

    CAS  PubMed  Google Scholar 

  6. Dvorak HF et al. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation Int Arch Allergy Immunol 1995 107: 233–235

    Article  CAS  PubMed  Google Scholar 

  7. Dachs GU et al. Targeting gene expression to hypoxic tumor cells Nat Med 1997 3: 515–520

    Article  CAS  PubMed  Google Scholar 

  8. Prentice H et al. Regulated expression of a foreign gene targeted to the ischaemic myocardium Cardiovasc Res 1997 35: 567–574

    Article  CAS  PubMed  Google Scholar 

  9. Boast K et al. Characterization of physiologically regulated vectors for the treatment of ischemic disease Hum Gene Ther 1999 10: 2197–2208

    Article  CAS  PubMed  Google Scholar 

  10. Shibata T, Giaccia AJ, Brown JM . Development of a hypoxia-responsive vector for tumor-specific gene therapy Gene Therapy 2000 7: 493–498

    Article  CAS  PubMed  Google Scholar 

  11. Modlich U, Pugh CW, Bicknell R . Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers Gene Therapy 2000 7: 896–902

    Article  CAS  PubMed  Google Scholar 

  12. Koshikawa N et al. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells Cancer Res 2000 60: 2936–2941

    CAS  PubMed  Google Scholar 

  13. Binley K et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer Gene Therapy 1999 6: 1721–1727

    Article  CAS  PubMed  Google Scholar 

  14. Griffiths L et al. The macrophage – a novel system to deliver gene therapy to pathological hypoxia Gene Therapy 2000 7: 255–262

    Article  CAS  PubMed  Google Scholar 

  15. Ruan H et al. Killing of brain tumor cells by hypoxia-responsive element mediated expression of BAX Neoplasia 1999 1: 431–437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Semenza GL, Wang GL . A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation Mol Cell Biol 1992 12: 5447–5454

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Liu Y et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer Circ Res 1995 77: 638–643

    Article  CAS  PubMed  Google Scholar 

  18. Shibata T et al. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes Int J Radiat Oncol Biol Phys 1998 42: 913–916

    Article  CAS  PubMed  Google Scholar 

  19. Baron U et al. Co-regulation of two gene activities by tetracycline via a bidirectional promoter Nucleic Acids Res 1995 23: 3605–3606

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by grants NS41403, CA86335 and CA87830 from the NIH, the Charlotte Geyer Foundation, the Pediatric Brain Tumor Foundation of the US, The Brain Tumor Society, and MBNA, NA. Oligonucleotides were synthesized by the Emory University Microchemical Core Facility.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to EG Van Meir.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Post, D., Van Meir, E. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther 8, 1801–1807 (2001). https://doi.org/10.1038/sj.gt.3301605

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301605

Keywords

This article is cited by

Search

Quick links